Results presented at the European Society of Cardiology Congress 2023 further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular events and demonstrate particular benefit in those with diabetes. In this interview, Stephen J. Nicholls MBBS, PhD, FACC and Erin D. Michos, MD, MHS, FACC, discuss the total events analysis from the CLEAR Outcomes trial. 

 This ACCEL episode is part of an ACC course titled Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape. Educational grant support is provided by Esperion. More content will be available here soon. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

What is known about the use of wearables and their impact on health outcomes and healthcare use among patients with atrial fibrillation.  

 In this interview, Dipak Kotecha MBChB, PhD and Sidney C. Smith Jr. MD, MACC, discuss “ESC Late-Breaker: RATE-AF trial wearables study.” 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In selected countries from each of the six WHO regions, the INTERASPIRE survey is being conducted to provide a unique picture of CHD patients, their cardiometabolic, renal and biomarker status, lifestyle and therapeutic management, and the quality of preventive care in their region.

In this interview, John W. McEvoy MB, BCh, BAO, MHS, and William E. Boden MD, FACC discuss INTERASPIRE: An International Survey of Secondary Prevention of CVD.

Subscribe on Apple Podcasts  Subscribe on Google Play  Subscribe to ACCEL

Understanding, recognizing and effectively treating PAD has the potential to dramatically alter a patient’s life. A patient’s ability to walk, quality of life, and longevity can all be profoundly impacted. 

In this interview, Sasanka Jayasuriya, MD, FACC, Douglas Weaver MD, MACC, and Sun Moon Kim MD, FSCAI, FACC, discuss Contemporary Therapy in PAD That Every Cardiologist Should Know. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Cardiorenal syndromes cause fluid retention and venous congestion that, in turn, damages the function of vital organs. Providers should have zero tolerance for excessive fluid retention. Aggressive diuretic treatment seems particularly beneficial in patients who are hospitalized for decompensated heart failure. 

 In this interview, Paolo Colombo MD, FACC, and William E. Boden MD, FACC, FAHA, discuss Renal Considerations in the Management of Heart Failure. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Patients with heart attacks often have a lifesaving procedure to open up the narrowed or blocked coronary artery responsible for their heart attack. In about 30-50% of these patients, additional blockages or narrowings that did not cause the heart attack are found. Evidence doesn’t support clinical decision-making on how to identify which of these additional narrowings to open or whether to open all of them. 

In this interview, Shamir R. Mehta MD, MSc, FACC, and Matt Cavender MD, MPH, FACC, discuss Managing MVD in STEMI: What We Know and What We Still Need to Learn!. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Michael Kontos, MD, FACC, and John Gorcsan III, MD, FACC discuss High Sensitivity Troponins in Evaluation of Acute Chest Pain. 

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

As device therapy continues to evolve, there is an emerging opportunity to address tricuspid valve disease in patients who previously were overlooked due to their high surgical risk. Proper patient selection and medical optimization will be critical factors driving the success or failure of these nascent technologies. 

 In this interview, Sean Pinney MD, FACC, FAST, FHFSA, and Sidney C. Smith Jr. MD, MACC, discuss "Optimal Medical Therapy for Tricuspid Regurgitation: An Oxymoron?"

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In patients with heart failure, viability tests (special heart scans) allow clinicians to distinguish permanently damaged (scarred) parts of the heart from those that may be hibernating and could recover function. Following decades of use based on this theory, the utility of viability tests at predicting prognosis and recovery of heart function has been scientifically tested in the REVIVED Viability study, the results of which could dramatically change the way heart failure patients are assessed and managed. 

  In this interview, Divaka Perera MD, FRCP, and Matt Cavender MD, MPH, FACC discuss Revascularization for Heart Failure. 

  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

HCM is present in 1 in 500 individuals around the world.  While most patients with HCM can have a normal lifestyle and longevity, there are important issues regarding family screening, sudden cardiac arrest risk, and therapies. 

In this interview, Steve R. Ommen MD, FACC, and Matthew Martinez MD, FACC, discuss Hypertrophic Cardiomyopathy: Genetics, Natural History, Evolution and Septal Reduction Therapies. 

Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL